Universite de Toulouse, CRCT, INSERM UMR 1037, 2 Avenue Hubert Curien, 31037 Toulouse, France.
Universite de Toulouse, Pharma-Dev, Institut de Recherche pour le Developpement (IRD) UMR 152, Faculte des Sciences Pharmaceutiques, F-31062 Toulouse, Cedex 09, France.
Curr Cancer Drug Targets. 2019;19(5):349-359. doi: 10.2174/1568009618666180628101059.
The use of photodynamic therapy in cancer still remains limited, partly because of the lack of photosensitizer (PS) specificity for the cancerous tissues. Various molecular tools are available to increase PS efficiency by targeting the cancer cell molecular alterations. Most strategies use the protein-protein interactions, e.g. monoclonal antibodies directed toward tumor antigens, such as HER2 or EGFR. An alternative could be the targeting of the tumor glycosylation aberrations, e.g. T/Tn antigens that are truncated O-glycans over-expressed in numerous tumors. Thus, to achieve an effective targeting, PS can be conjugated to molecules that specifically recognize the Oglycosylation aberrations at the cancer cell surface.
光动力疗法在癌症中的应用仍然受到限制，部分原因是缺乏对癌组织具有特异性的光敏剂（PS）。各种分子工具可用于通过靶向癌细胞分子改变来提高 PS 效率。大多数策略利用蛋白质-蛋白质相互作用，例如针对肿瘤抗原的单克隆抗体，例如 HER2 或 EGFR。另一种选择可以是针对肿瘤糖基化异常的靶向，例如 T/Tn 抗原，这些抗原是在许多肿瘤中过度表达的截断 O-聚糖。因此，为了实现有效的靶向，PS 可以与专门识别癌细胞表面 Oglycosylation 异常的分子缀合。
